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Abstract: Embryonal tumors of the central nervous system represent a heterogeneous group 
of childhood cancers with an unknown pathogenesis; diagnosis, on the basis of histological 
appearance alone, is controversial and patients’ response to therapy is difficult to predict. 
They encompass medulloblastoma, atypical teratoid/rhabdoid tumors and a group of primitive 
neuroectodermal tumors. All are aggressive tumors with the tendency to disseminate 
throughout the central nervous system. The large amount of genomic and molecular data 
generated over the last 5–10 years encourages optimism that new molecular targets will  
soon improve outcomes. Recent neurobiological studies have uncovered the key role of 
microRNAs (miRNAs) in embryonal tumors biology and their potential use as biomarkers 
is increasingly being recognized and investigated. However the successful use of 
microRNAs as reliable biomarkers for the detection and management of pediatric brain 
tumors represents a substantial challenge. This review debates the importance of miRNAs in  
the biology of central nervous systemembryonal tumors focusing on medulloblastoma and 
atypical teratoid/rhabdoid tumors and highlights the advantages as well as the limitations of their 
prospective application as biomarkers and candidates for molecular therapeutic targets. 
Keywords: central nervous system (CNS) embryonal tumors; medulloblastoma; atypical 
teratoid/rhabdoid tumors; microRNAs (miRNAs); biomarkers 
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1. Introduction 
Embryonal tumors of the central nervous system (CNS) are biologically heterogeneous neoplasias 
that share the tendency to disseminate throughout the nervous system via cerebrospinal fluid (CSF) [1]. 
They include childhood medulloblastoma (MB), the most frequent malignant brain tumors in children, 
and atypical teratoid/rhabdoid tumors (AT/RT), a highly malignant group of tumor predominantly 
manifesting in the CNS of young children [1,2]. Survival rates of pediatric brain tumor patients  
have significantly improved over the last years due to the developments in diagnostic techniques, 
neurosurgery, chemotherapy, radiotherapy, and supportive care [3]. However, brain tumors are still an 
important cause of cancer-related deaths in children. Diagnosis of brain tumors is currently based on the 
detection of symptoms and neuro-imaging abnormalities, which appear at relatively late stages in the 
pathogenesis. However, the underlying molecular responses to genetic and environmental insults begin 
much earlier and microRNA (miRNA) networks are critically involved in these cellular regulatory 
mechanisms [4]. Profiling miRNA expression patterns could thus facilitate pre-symptomatic disease 
detection [5]. By peering into the black box of how pediatric brain tumors develop, preclinical studies, 
using tumor profiling and several primary and permanent cancer cell lines, have implicated many 
miRNAs in the development, progression and metastasis of embryonal tumors [4,6,7]. It is encouraging 
to note that a great deal of progress has been made recently in dissecting miRNA pathways associated 
with the biology of embryonal brain tumors and a number of miRNAs have been identified as potential 
candidates for molecular therapeutic targets [8]. Although therapeutical targeting of miRNAs has not yet 
been applied in clinical trials as single treatment agent regiments, it has recently been demonstrated both 
in vitro and in vivo that miRNA-targeted therapy may be useful in combination with conventional 
chemo-radiotherapy to sensitize cancer cells [9]. This review describes the current understanding of the 
roles of miRNAs in pediatric MB and AT/RT brain tumors, and highlights the advantages and the 
limitations of miRNAs as potential markers and therapeutic targets for MB and AT/RT. 
2. miRNAs 
miRNAs constitute an evolutionarily conserved class of small non-coding RNAs that  
post-transcriptionally suppress gene expression via sequence-specific interactions with the 3'-UTRs of 
mRNA targets [10]. The function of a miRNA is defined by the genes it targets and the effects exploited 
on its expression. A given miRNA can target several hundreds genes, and around 60% of mRNAs  
have predicted binding sites for one or multiple miRNAs in their UTR. Two major silencing  
mechanisms have been identified for miRNAs: miRNAs can inhibit translation by inhibiting translation 
initiation/elongation or can promote mRNA degradation. Under normal conditions, miRNAs act as 
moderate regulators fine-tuning gene expression, but under conditions of stress or disease, they appear 
to exert more pronounced functions. One of the most interesting aspects of miRNA biology is that one 
single miRNA can regulate multiple genes that are involved in a specific signaling cascade or cellular 
mechanism, making miRNAs potent biological regulators. The frequent aberrant expression and 
functional implication of miRNAs in human cancers, including pediatric nervous system tumors [4], and 
the availability of highly sensitive expression measurements techniques, have lifted these small cellular 
components to the ranks of ideal measurable tumor biomarkers and preferred drug targets [11]. However 
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translation of these markers to clinical settings remains a considerable challenge and has proved more 
difficult than might have been expected. 
2.1. miRNA Detection Methods: Advantages and Concerns 
Alterations in the expression of miRNAs in diseases can be revealed by technologies that accurately 
assess changes in the content of miRNAs. The development of methods for detecting miRNAs has 
become a research field in its own right [12]. Ideal miRNA detection/profiling method should be 
sensitive enough to provide quantitative analysis of expression levels, reproducible, capable of 
processing multiple samples in parallel, and finally, easy to perform without the need for expensive 
reagents or equipment [13]. Currently, various applications are available to detect miRNAs (Table 1) 
and determine their abundance, including microarray-based [14] and PCR-based approaches [15], 
Northern blot analysis with radio-labeled probes [16], in situ hybridization [17] and high-throughput 
sequencing [18] (Figure 1). However, none of these methods is perfect and all have advantages and 
inherent limitations [12]. 
2.1.1. miRNAs Detection by Microarray Approach 
Microarray technology is based on nucleic acid hybridization between target miRNAs molecules and 
their corresponding complementary probes. Microarray technology is a powerful high-throughput tool 
capable of monitoring the expression of thousands of miRNAs at once within tens of samples processed 
in parallel in a single experiment. It is usually used to conduct a genome-wide analysis of miRNA 
expression of normal and/or disease samples, including cancer, and to distinguish expression  
signatures associated with diagnosis, prognosis and therapeutic interventions [19]. The technique 
involves oligonucleotide probes with the same sequence as the target miRNAs which are immobilized 
on glass slides forming a ready-to-use miRNA microarray. The isolated miRNAs are converted to cDNA 
by reverse transcription, labeled with fluorescent dye and then hybridized on the microarray. After a 
series of washing steps to remove any unbound cDNAs, the hybridized miRNAs are detected by a 
microarray scanner to determine the fluorescence intensity on each probe spot, which represents the level 
of expression of each target miRNA from the initial RNA sample. Several technical variants of miRNA 
arrays have been independently developed. The main differences include probe design, immobilization 
chemistry, sample labeling, and microarray chip signal-detection methods [20]. These genome-wide 
miRNA microarray platforms have the advantage of generally being less expensive than the other 
profiling methods and yet they allow large numbers of parallel measurements. The main disadvantage 
of these techniques is that they are unable to identify novel miRNAs. Application of microarray 
technology is also challenged by several innate properties of miRNAs, mainly the short length of 
miRNAs that offers little room to fine-tune the hybridization conditions. The low abundance of miRNAs 
fraction of total cellular RNA (<0.01%) and the imperfect specificity for miRNAs that are closely related 
in sequence and may differ by a single nucleotide, represent yet additional challenges which significantly 
decrease the sensitivity and specificity of microarrays. Another drawback of microarray technology is the 
lack of ability to perform absolute quantification of miRNA abundance [21]. Nevertheless microarrays are 
considered to be the best tool for comparing relative abundance of specific miRNAs between two states 
such as “experimental” vs. “control” or “diseased” vs. “healthy” samples [21]. Finally, a large quantity 
Int. J. Mol. Sci. 2014, 15 21557 
 
 
of RNA is required for testing, and microarray chips are also very expensive to fabricate. However, if 
routinely implemented in basic and clinical research laboratories, microarray-based miRNA expression 
profiling has the certain potential to lead to the discovery of novel biomarkers and therapeutic targets 
(reviewed in [21]). 
Figure 1. miRNA detection/profiling methods. miRNAs are usually extracted from various 
specimen types such as cell culture, fresh tumor tissues, formalin-fixed paraffin embedded 
tumors or cerebrospinal fluid. miRNA isolation methods/kits which are widely available 
commercially typically use a chemical extraction combined with a purification step that 
involves binding and eluting from a silica column. Various methods can be used to  
assess miRNA quality after extraction including spectrophotometry, automated capillary 
electrophoresis with Bioanalyzer. For cerebrospinal fluid (CSF), where usually RNA yields 
are too low, determining the recovery of spiked-in synthetic miRNA oligonucleotides is useful. 
miRNA profiling can be determined with one of the listed methods: Microarray, quantitative 
reverse transcription PCR (q-RT-PCR), In Situ Hybridization (ISH), Northern blot or RNA 
sequencing. FFPE: Formalin-Fixed Paraffin-Embedded. 
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2.1.2. Real-Time-PCR-Based Detection of miRNAs 
Real-time PCR is the gold standard for gene expression quantification. Although global expression 
profiling assays are useful to provide a broad overview of the presence and the regulation of miRNAs, 
these data normally require a confirmation by more specific approaches. To date the most commonly 
used method to detect specific miRNAs is the real-time PCR analysis. This approach relies on reverse 
transcription of miRNA to cDNA, followed by quantitative PCR (qPCR) with real-time monitoring of 
reaction product accumulation. Commercially available customizable plates and microfluidic cards can 
be designed either to examine a small set of miRNAs or to provide more comprehensive coverage by 
large-scale profiling of hundreds of miRNAs [21]. Because of its high level of sensitivity, accuracy and 
its ability to differentiate between single base mismatches, quantitative reverse transcription PCR  
(q-RT-PCR) is accepted as a powerful technique in comparative expression analysis in life sciences and 
medicine [12]. Another appealing aspect of this approach is the practical ease of incorporation  
into the workflow of clinic laboratories. A hurdle in performing highly parallel q-RT-PCR is the challenge 
for scientists to design a conventional PCR assay from miRNAs averaging around 22 nt in length.  
The optimal reaction conditions may also vary substantially between miRNAs owing to sequence-specific 
differences in primer annealing. A limitation of q-RT-PCR technique is that the reaction cannot identify 
novel miRNAs. Another major drawback is the requirement for special equipment that is likely not 
available in most laboratories, which makes widespread application of this method difficult [22]. 
2.1.3. Northern Blot Analysis for miRNAs Detection 
Northern blotting was used to identify the very first miRNAs, and still remains a gold standard for 
miRNA expression analysis [23]. Although it is fairly time consuming and requires large amounts of 
RNA, it is the only approach that will visualize the expression product of a miRNA. After isolation  
of total RNA from cells or tissue, the small RNAs are fractionated by electrophoresis on a high  
percentage gel. After transferring these small RNAs from the gel onto a nitrocellulose membrane,  
to allow detection by hybridization with fluorescent or radio-labeled probes that are complementary to 
the target miRNA, the RNA is fixed onto the membrane by UV cross-linking and/or baking the 
membrane. Because of the small size and the low abundance of miRNA molecules, the use of an 
oligonucleotide probe with high sensitivity is essential for the detection of a given miRNA [24]. Northern 
blotting technique allows the validation of predicted miRNAs by the examination of their expression 
levels and the determination of their sizes. However, there are several technical limitations that prevent 
the routine use of Northern blotting as miRNA expression profiling tool in clinics. Mature miRNA 
molecules are very short and their abundance in total RNA is also very low, leading to a poor sensitivity 
of routine Northern blot analysis. Moreover this method is very time-consuming and not practical in 
clinical studies in which the detection of a large number of miRNAs might be required; its use in 
diagnostic is also limited by the relatively large amount of RNA sample required and the multiple 
handling steps.  
Int. J. Mol. Sci. 2014, 15 21559 
 
 
2.1.4. In Situ Hybridization (ISH) for miRNA Detection 
ISH is an important tool used to detect miRNA accumulation in tissue sections or fixed cells.  
The technique uses labeled complementary nucleic acid sequences to detect a single strand of DNA or 
RNA. The advantage of ISH is the ability to monitor specific miRNA expression at the cellular or even 
at sub-cellular level, which results in asemi-quantitative analysis of miRNA expression. However, 
detection of miRNAs by ISH is technically challenging because of the small size of the target sequences 
and the low expression level of some miRNAs. Hence the use of this technique as a routine tool for 
miRNA expression profiling tool in diagnostics will likely remain limited by the low quantification 
power and by the low throughput nature of this methodology. 
2.1.5. miRNA Detection by High-Throughput Next-Generation Sequencing Platforms 
All of the techniques described above depend on hybridization and are restricted to the detection and 
profiling of previously identified miRNA sequences. Next generation sequencing platforms do not 
depend on hybridization and do not require previous information. The sequence-based methods for 
miRNA profiling determine the nucleotide sequence of miRNAs and involve RNA isolation, ligation of 
linkers to both 3' and 5' ends, reverse transcription, and PCR amplification, followed by the “massively 
parallel” sequencing of millions of individual cDNA molecules. Bioinformatic analysis of the sequence 
reads identifies both known and novel miRNAs in the data sets and provides relative quantification using 
a digital approach [22]. High-throughput sequencing methods permit high-resolution views of expressed 
miRNAs over a wide dynamic range of expression levels and the discrimination of miRNA family 
members that differ in only a nucleotide. Unlike profiling of miRNAs based on microarray techniques, 
deep sequencing measures absolute abundance and allows the discovery of novel miRNAs. Therefore 
deep sequencing methods are emerging as the best tool for studying miRNA expression also because 
they can reliably be used for miRNA detection in fresh frozen paraffin-embedded specimens, thus making 
large-scale clinical studies possible. In addition high-throughput sequencing of miRNAs have successfully 
revealed the differential expression of miRNAs in several cancerogenic and pre-carcinogenic lesions [13,25], 
suggesting that they can be used in diagnostics for early detection and for assessment of tumor 
aggressiveness [12]. 
Potential limitations are high costs and the computational infrastructure required for data analysis  
and interpretation [26]. 
In summary, microarray technology based methods appear to be best suited for detection of miRNA 
profiles, although RT-PCR may be the method of choice in a clinical settings if a combination of only  
a few miRNAs is used as marker. In addition, if it is important to know in which cell type a  
specific miRNA is expressed, ISH methods may be required. Despite being expensive some consider 
next-generation sequencing as the method of choice for studying small RNA expression. In contrast  
to the other methods, this platform is hybridization-independent, more sensitive and accurate in 
discriminating miRNA family members that could differ by only a single nucleotide and can be used to 
simultaneously detect known and yet unknown miRNAs. 
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2.2. miRNA Target Determination 
In the past decade the number of discovered genes encoding miRNAs has risen exponentially and 
researchers have gained substantial in-depth knowledge of the basic mechanism of action of miRNAs, 
but the main challenge still remaining is the identification of the tangible direct targets of these 
molecules, to understand how they regulate so many biological processes in both healthy and diseased 
tissue. Many technologies have been developed in the past few years, all with their own pros and cons [27]. 
Initial insight into miRNA targets can be obtained bioinformatically through a number of available 
programs that predict potential mRNA targets for individual miRNAs. Although it is important to 
confirm these predictions using miRNA target validation techniques, bioinformatic target prediction is 
often the first step toward defining the function of a specific miRNA. Currently, there are a number of 
freely available programs, such as miRanda (http://www.microRNA.org), microCosm (previously 
known as miRBase targets, http://www.mirbase.org), Targetscan (http://www.targetscan.org), or PicTar 
(http://pictar.mdc-berlin.de) that predict which mRNAs can potentially be targeted by a given miRNA 
or which miRNAs might be able to target a certain gene of interest. Main characteristics that these 
programs use to determine whether a miRNA can potentially target an mRNA include sequences 
complementarity between the 5' seed region of the miRNA (usually 2–8 bases) and the 3'-UTR sequence 
of a target gene. Thermal stability of the mRNA/miRNA duplex is often also taken into account; 
reviewed in [22]. After the identification of potential miRNA target genes, the physical binding of 
miRNA to candidate mRNAs and the subsequent translational modulation needs to be confirmed.  
A common approach for miRNA target verification is by cloning the 3'-UTR of a predicted mRNA target 
into a luciferase reporter. By linking the target UTR to the luciferase reporter, a change in luciferase 
signal will indicate whether a miRNA can bind to the UTR and regulate the expression of the gene.  
For this approach cell lines are chosen due to their transfectability (for example, HEK293 cells); however, 
tissue-specific miRNA biogenesis and binding warrants that these studies be performed in relevant cell 
line models resembling the tissue of origin [27]. 
3. miRNA Implications in CNS Embryonal Tumors 
miRNAs are implicated in diverse biological processes including cell self-renewal and pluri-potency [28] 
and as etiologic genes in various human malignancies [29]. Patterns of miRNA expression have been 
shown to distinguish tumor types and to predict tumor behavior [30]. However, their role in malignant 
pediatric brain tumors remains largely unexplored. 
3.1. miRNAs Associated with Neuronal Development and Disorders 
Studying the expression pattern of miRNAs during mammalian brain development, Kim et al. [31] 
identified miR-103, miR-124a, miR-128, miR-323, miR-326, miR-329, miR-344 and miR-192-2 to be 
expressed in the rat cortex and cerebellum during neural differentiation and development, reviewed in [32]. 
Using human embryonic cells that differentiate into neurons upon retinoic acid treatment, Sempere et al. 
showed that miR-9/9, miR-103-1, miR-124a, miR-124b, miR-128, miR-135, miR-156 and miR-218 are 
coordinately induced during the neural differentiation process [24]. Remarkably some of these miRNAs 
were reported to be also active in neuro-developmental disorders [33]. The notion that cancer is fuelled 
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by self-renewing stem cells is gaining prominence, and so is the idea that miRNA can direct cell fate. 
Yu et al. has brought the two fields together by showing that a single miRNA molecule “miRNA let-7” 
can regulate stem-ness in cancer cells [34]. The important role of stem cells both in normal tissue and 
cancer development has driven much of the research into neural cancer stem cell biology. Silber et al. 
reported that miR-124 and miR-137 induce differentiation of neural stem cells and glioblastoma stem  
cells [35]. Desanomi et al. reported that miR-34 deficiency is involved in the self-renewal and survival of 
cancer stem cells, and that in cancer cells lacking functional p53, restoration of miR-34 was able to  
re-establish the tumor suppressing signaling pathway [36]. The research in this area has recently led to 
the identification of specific miRNA genes responsible for embryonal stem cells (ESCs) proliferation 
and differentiation and for the initiation and progression of cancer stem cells [34–38]. miR-17/92 is an 
example of an miRNA associated with MB and neuronal stem cell biology. It promotes neural stem cells 
development by modulating its cell-fate decision and it is also involved in cancer stem cell maintenance 
and in MB biology [39]. Other miRNAs such as miR-7, miR-9 and repression of miR-124 were reported 
to be associated with MB biology and neuronal differentiation [40–42] while miR-125b, miR-324-5p, 
and miR-326 regulate SHH signaling in cerebellar granule neuron precursors and MB cells [4]. 
Interestingly, specific miRNAs such as miR-302 were recently found to be capable of reprogramming the 
cancer cells back into a pluripotent embryonic stem cell-like state, which then could be induced to mature 
into tissue-specific cells [43]. Together these reports suggest that miRNA expression is vital for normal 
as well as abnormal embryonic stem cells development that can lead to cancer stem cell initiation, 
reviewed in [36]. Cancer stem cells have been identified, isolated and characterized recently in 
embryonal neural malignancies including MB [44–48]. With the knowledge that MB harbors  
cancer-initiating cells with stem cell properties, scientists are making a great effort to understand the 
involvement of aberrantly expressed miRNAs in embryonal cancer stem cells and to elucidate the 
mechanisms which distinguish these cells from normal stem cells. Functional studies on miRNAs within 
the cancer stem cells of MB will be crucial for elucidating the mechanisms behind oncogenesis in these 
deadly malignancies and might reveal novel therapeutic targets. 
3.2. Biological Relevance of miRNAs in MBs 
MBs are primary malignant embryonal tumors of the central nervous system and represent more than 
one fifth of all pediatric brain tumors [1,3]. While the prognosis has traditionally been based on 
conventional histopathology and clinical staging, in recent years it has become apparent that the inherent 
biology of the tumor plays a significant part in predicting survival [49]. Recent advances in molecular 
biology and integrated genomics have led to an improved understanding of the genetic abnormalities 
and alterations in cell signaling pathways associated with MBs. Four distinct molecular subgroups of 
MB have been identified (WNT (wingless), SHH (sonic hedgehog), Group 3, and Group 4) [50–52]. 
Profiling of these subgroups revealed distinct genomic events, several of which represent prognostic and 
predictive biomarkers as well as targets for therapy [50–54]. Specifically, stratification of patients into 
their respective subgroups has profound prognostic impact, wherein therapy can be de-escalated in 
patients with favorable prognosis, and intensified therapy or novel agents can be considered in patients 
with poor prognosis [55]. However, despite considerable progress, more effort is still needed to  
fine-tune the identification of specific biological alterations that could be targeted by molecular specific 
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therapies. In this scenario miRNA research is emerging together with the established evidence regarding 
the key roles of these molecules in this cancer. Despite the fact that miRNAs are involved in the 
tumorigenesis of a range of different tumors, the knowledge about the prognostic, diagnostic, and/or 
therapeutic target potential of these molecules in brain cancer, especially MBs, is still at an early stage [8]. 
3.2.1. miRNAs Function as Oncogenes or Tumor Suppressors in MB 
The class of genes that function as tumor suppressors and oncogenes in MB have recently been 
expanded to include the miRNA family [41,42,56,57] (Table 1). miR-124a was amongst the first to be 
characterized as a tumor suppressor miRNA in MB [58]. This miRNA is a brain-enriched miRNA found 
to be expressed in the external granule cells of the cerebellum, reported to be cells of origin of MBs [59–61]. 
miR-124a was found to be decreased in MB cells compared to normal cerebellum and restoration of its 
function inhibits MB cell proliferation [58]. Pierson et al. [58] reported that cyclin dependent kinase 6 
(CDK6) and solute carrier family 16, member 1 (SLC16A1) are functional targets for miR-124a. Both 
genes were reported as an adverse prognostic marker in MB [62,63]. Ferretti et al. [4] identified a set of  
four up-regulated miRNAs (let-7g, miR-19a, miR-106b and miR-191) that are capable of distinguishing 
MB patient samples with aggressive vs. non aggressive histological MB variants. Furthermore, the 
authors observed in MB samples impaired expression of specific miRNAs that are known to be expressed 
during neuronal development such as (miR-9, miR-125a, miR-128a, miR128b and miR-181b), 
suggesting that some of these miRNAs might be involved in MB tumorigenesis [64]. Interestingly,  
these miRNAs were previously identified before in other brain tumors such as glioblastomas [65]. 
Experimentally, increasing the expression of miR-9 or miR-125a decreased MB cells survival and 
promoted MB tumor growth arrest suggesting a role for both miRNAs as tumor suppressors [66]. In a 
recent survey of miRNA expression in pediatric brain tumors including MB, miR-216, miR-135b, miR-217, 
miR-592 and miR-340 were found to be upregulated, whereas miR-92b, miR-23a, miR-27a, miR-146b and 
miR-22 were found to be downregulated, compared to normal brain tissue [67]. MB genome-wide 
miRNA expression profiling studies have revealed close associations of miRNA clusters with molecular 
and clinical subgroups [31,63,68,69]. In these studies miR-21 [70] was found to be up-regulated across 
all MB subgroups compared to normal cerebellum, while a miR-17/92 cluster was reported by Northcott 
and colleagues to be significantly up-regulated specifically in SHH-driven MBs [63,71]. Their results 
were confirmed in a report by Uziel et al. that showed miR-17/92 promoting proliferation of MB cell 
lines in vitro and contributing to the development of MB in vivo [63,71]. Other labs also associated  
miR-17/92 and miR-106b-25 cluster over-expression with both human and mouse SHH MBs [69,72]. 
Moreover miR-17/20 and miR-19a/b inhibitors decreased tumor growth in SHH MB cells in vitro and 
in animals bearing flank or cortical SHH MB allografts [73] suggesting that inhibitors targeting the  
miR-17/92 cluster could be therapeutically useful in SHH MBs [74]. Over-expression of other oncogenic 
miRNA clusters such as miR-183-96–182 were reported in MB subgroups characterized by genetic 
amplification of MYC, and not in SHH MBs [68] and promote metastasis, a hallmark of MYC aggressive 
MBs [75]. Ferretti and colleagues found additional miRNAs differentially regulated in MYC  
over-expressing MBs [69]. However, it is not known whether these miRNAs are directly regulated by 
MYC; reviewed in [74]. Cho et al. discovered a previously unidentified molecular subgroup, genetically 
characterized by gain of MYC copy number, miR-183-96–182 upregulation and significantly associated 
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with lower rates of event-free and overall survival [76]. For the WNT MB subgroup, miR-193a,  
miR-224/miR-452 cluster and miR-148a were reported to have potential tumor/metastasis suppressive 
activity and were found to be over-expressed in WNT signalling-associated MB [77]. To summarize, 
knowledge about miRNA expression signatures in distinct MB subtypes provides new insight into the 
molecular pathogenesis of MB tumors and highlights the hope of potential translation of such valuable 
information into therapy. 
Table 1. MicroRNAs (miRNAs) involved in medulloblastoma (MB) biology as oncogenes 
or tumor suppressors. 
miRNAs (miRs) Targets References 
Oncomirs 
miR-21 PDCD4 [78] 
miR-517c, miR-520g miR-517c WNT/JNK signaling, miR-520g ABCG2 [79,80] 
miR-221, miR-222 p27Kip1 [6] 
miR-183-96–182 
cluster 
Undefined, however knockdown of the full miR-183-96–182 
cluster results in enrichment of genes associated with apoptosis 
and dysregulation of the PI3K/AKT/mTOR signaling axis 
[68] 
miR-17/92 TSP-1, Bmi-1, PTEN, PP2A [63,81,82] 
miR-214 Gli1 [4] 
miR-30b, miR-30d Undefined, Both miRNAs are part of an amplicon containing the 
KHDRBS3 gene on 8q24.22 in MB cell lines [83] 
miR-106b p21 [69,84] 
Tumor Suppressors miRNAs 
miR-125a t-TrkC [69] 
miR-9 REST/NRSF, Hes1 [39,69] 
miR-125b, miR-324-5p, 
miR-326 PKM2, SMO, Notch [4,85] 
let-7 RAS, STAT3 [69,86] 
miR-199b-5p HES1, Notch pathway, ErbB2 [87] 
miR-124a CDK6, SLC16A1, REST, BAF34a, RB1,t-TrkC [35,58,60,88,89]
miR-218 EGFR, Bcl-2, B-catenin and MAPK9 [84,90] 
miR-31, miR-153 miR-153 is found in high ErbB2 expressing MB [69,90] 
miR-128a, miR-128b, 
miR-181b Bmi-1 [64,91] 
let-7 miRNA family HMGA2 [7] 
3.2.2. miRNAs Associated with MB Metastasis 
Metastases are responsible for the majority of MB-related mortality, yet our understanding of the 
molecular circuitry coordinating this process is fragmentary. miRNAs are believed to play a key role as 
suppressors or promoters of metastasis according to their mRNA targets [92,93]. miR-21 up-regulation  
is associated with metastasis and cell migration in a variety of solid tumors including breast, lung, colon, 
prostate, pancreas and stomach cancers, as well as brain tumors such as glioblastoma [78,94,95]. Our lab 
recently reported the upregulation of miR-21 in MB cells, while miR-21 inhibition decreased MB cell 
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migration in vitro. Subsequent studies have identified other miRNAs as either promoters or suppressors 
of metastasis in MBs [96,97]. miR-106b was found to be overexpressed in MBs and directly interacting 
with PTEN. Inhibition of miR-106b in MB cells reduced cell migration and invasion potential [96].  
In another interesting study, miR-182 was found to be able to contribute to leptomeningeal metastatic 
dissemination in non-SHH MB [75]. Additionally miR-193a, miR-224/miR-452 cluster, and miR-148a 
were reported as exerting potential metastasis suppressor activity [31], while miR-199-5p was described 
as an inhibitor of MB metastasis [87]. Along the same lines, miR-219 suppresses invasion and metastasis 
through targeting CD164 [97]. 
3.3. Clinical Relevance of miRNAs in MBs 
Risk stratification and prognosis assessment have become a major concerns in the era of personalised 
medicine. Although gene expression profiling has reached a plateau in this regard, recent miRNA studies 
show new great promises [31,63,68], reviewed in [98]. Multiple reports have noted the utility of miRNAs 
for the prognostics and risk stratification of MBs (Figure 2). Moreover, miRNA expression profiles have 
been used to distinguish tumor histo-types. For example the oncogenic group miR-let7g, miR-106b, 
miR-191 and miR-19a are up-regulated in more aggressive MB anaplastic histotype with respect to 
classic and/or desmoplastic tumors [69]. The potential clinical utility of miRNAs extends beyond the 
realm of tumor classification to other important clinical measures, such as prognosis and treatment 
response. The low expression of tumor suppressor miRNAs, such as miR-199-5p, was found to be 
predictive for poor prognosis [87]. Low expression of miR-128b and miR-181b has been reported to 
correlate with MB disease risk [64,69], while both miR-31 and miR-153 are down-regulated in clinical 
high-risk MB patients [56,64,69]. On the other hand, oncogenic miRNAs, such as miR-125b, miR324-5p, 
and miR-326, promote progressive events in MBs [4]. Moreover, Weeraratne and colleagues reported 
that increased expression of the miR-183-96–182 cluster characterizes the most clinically aggressive 
subgroup and is associated with genetic amplification of MYC [68]. The same trend was observed when 
the miR-183-96–182 cluster was found to be significantly associated with non-SHH MBs, while miR-182 
promotes metastasis, a hallmark of aggressive MBs [75]. Our group recently identified miR-9 as  
a methylation-silenced tumor suppressor that could be a potential candidate predictive marker for MB 
with poor prognosis [39]. The investigation demonstrated that LC/A MB samples possess lower miR-9 
expression compared to the other variants and that miR-9 under-expression is associated with poor 
prognosis in 34 patient samples of MB. The lower overall survival probability of patients with low miR-9 
expression that also tends to have a more severe pathological grade suggests a strong trend towards 
prognostic significance. Moreover, in line with previous reports, high expression of the main miR-9 
target gene (HES1, hairy and enhancer of split 1 homolog), correlated significantly with lower overall 
survival in a distinct cohort of 129 MB samples [76]. In summary, although the full potential of miRNAs 
as prognostic factors awaits the results of larger prospective studies and further verification steps, the 
above mentioned data imply that in the near future miRNAs may have a wide clinical applicability as 
diagnostic and prognostic biomarkers for MB patients. 
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Figure 2. miRNAs associated with outcome prediction in MB patients. ↑: up-regulated;  
↓: down-regulated. 
 
3.4. Biological Relevance of miRNAs in CNS Atypical Teratoid/Rhabdoid Tumors 
CNS AT/RT are highly malignant central nervous system neoplasms that usually affect very young 
children and are typically deadly despite very aggressive treatment [99,100]. A standardized and 
effective approach for the treatment of this tumorremains elusive [101]. Rhabdoid tumors predominantly 
arise in the kidney and brain, but they can also be found in a deep axial location, such as the neck  
or the paraspinal region [102]. Different forms of rhabdoid tumors can be similar in their aggressiveness, 
histological features, and loss of function of INI1/hSNF5 mapping on chromosome 22 [103,104].  
From clinical experience, infants and children with rhabdoid tumors respond very poorly to 
chemotherapy and radiotherapy [105–107], although this remarkable resistance to both cytostatic drugs 
and radiotherapy has not yet found a convincing explanation at the molecular level. Because of the rarity 
of the disease, to date few miRNAsin AT/RT have been studied (Table 2). Sredni et al. [6] demonstrated 
that overexpression of miR-221/222 inhibited the expression of the tumor suppressor and inhibitor of 
cell cycle p27Kip1. The authors suggested that deregulation of miR-221/222 expression might be one of 
the factors contributing to oncogenesis and progression of AT/RT through p27Kip1 down-regulation and 
speculated that anti-miR-221/222 therapy might be an option for the treatment of these very aggressive 
and unresponsive tumors. Comparing miRNA expression in pediatric brain tumors and normal tissue 
controls, AT/RT samples showed high expression of miR-520b, miR-629, miR-221, miR-498 and miR-373, 
while miR-140, let-7b, miR-139, miR-153, and miR-376b were under-expressed [67]. To find new 
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potential therapeutic targets for the treatment of AT/RT, Zhang et al. [7] have recently searched for novel 
genomic aberrations by investigating the copy number and expression alterations of let-7a3/let-7b 
miRNA and correlated them with expression of high-mobility group AT-hook 2 (HMGA2) oncoprotein, 
a target of let-7 miRNA family, in 18 AT/RT samples. Their analysis demonstrated that HMGA2 was 
highly over-expressed in 83.3% of AT/RT tissues while let-7a3/let-7b miRNA copy number and 
expression were reduced. Restoration of let-7 miRNA or knockdown of HMGA2 expression 
significantly suppressed proliferation and colony formation and almost abolished the invasive potential 
of G401 Wilms’ tumor cell line. The authors suggested that the HMGA2 oncoprotein plays a critical 
role in the pathogenesis of AT/RT development and reconstitution of let-7 miRNA may provide a novel 
therapeutic strategy for the treatment of AT/RT patients. 
Table 2. miRNAs involved in atypical teratoid/rhabdoid tumors (AT/RT) biology as 
oncogenes or tumor suppressors. 
miRNAs (miRs) Targets References 
Oncomirs 
miR-517c, miR-520g miR-517c WNT/JNK signaling,  
miR-520g ABCG2 [79,80] 
miR-221, miR-222 p27Kip1 [6] 
miR-520b, miR-629, miR-498, miR-373 Undefined [67] 
Tumor Suppressors miRNAs 
miR-140, let-7b, miR-139, miR-153, miR-376b Undefined [67] 
let-7 miRNA family HMGA2 [7] 
miR-9 Undefined [40,69] 
4. miRNAs as Reliable Clinical Markers: Advantages and Challenges 
With the increasing implication of miRNAs in cancer development and progression, significant 
efforts are underway to use miRNAs as novel biomarkers with clinical applications [108–110]. miRNA 
expression profiling has been used to characterize embryonal and differentiated tissues of the nervous 
system [111], to discriminate cancer from normal tissue [70,93], and to differentiate primary from 
metastatic brain tumors [112]. Moreover, miRNAs identify individuals with increased disease risk, thus 
representing potential novel prognostic factors [113]. Of note, miRNAsncan also be detected circulating in 
several body fluids, including plasma, serum, cerebrospinal fluid, urine, and saliva [114–118]. Because of the 
significant differences that have been reported between the circulating miRNA expression profiles of 
healthy individuals and those of patients, it is encouraging to state that circulating miRNAs are likely to 
become a novel class of non-invasive and sensitive biomarkers for diagnosis and other clinical 
applications in human diseases [119]. In fact the use of circulating miRNAs as potential biomarkers is a 
rapidly evolving study field [108,120] and the number of publications has increased rapidly over the past 
two years. In the context of CNS diseases, several studies have demonstrated significant presence of 
specific miRNAs in CSF samples in patients with CNS lymphoma, glioma [117], metastatic brain 
cancers [116], and Alzheimer’s disease [121]. However, the true source of miRNAs in the body fluids 
and their exact secretory mechanism is still relatively unknown [122]. 
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4.1. Process of Biomarker Development 
The pathological progression from pre-neoplasia to cancer is accompanied by alterations in gene 
sequences, expression and function. Changes that occur exclusively, or more commonly, in cancer cells 
can be detected by specific molecular assays in tumor biopsy or in body fluids, and used as molecular 
indicators of cancer. These indicators/markers are useful in detecting cancer at early stages, assessing 
tumor burden, monitoring disease progression, and determining response to therapy [123]. Biomarkers 
can be broadly classified as prognostic or predictive markers that estimate disease-related patient 
trajectories and predict patient-specific outcome to different treatments [124]. Different conceptual phases 
of biomarker development have been proposed: phase one is the preclinical exploratory step that often 
begins by comparing tumor tissue with non-tumor tissue in order to identify characteristics unique to 
tumors that might lead to tests for clinical cancer detection. After the discovery stage, biomarkers must 
clear a number of practical hurdles before they can be considered for clinical practice. They have to 
undergo multiple defined stages of assay confirmation and validation. According to the US Food and 
Drug Administration (FDA), a “biomarker” is a “biomarker” that is measured in an analytical test system 
with well-established performance characteristics and for which there is an established scientific 
framework or body of evidence that elucidates the physiologic, toxicologic, pharmacologic, or clinical 
significance of the test results (Phase one) [125]. Phase two is a crucial subsequent step that evaluates 
the performance of biomarkers in distinguishing normal controls from cases with tumors (clinical 
validation) by testing the markers in tissues retrospectively collected from research cohorts [126]. This 
is best performed collaboratively with clinical and epidemiology centers. Phase three is the prospective 
screening phase. Ideally, biomarkers should be validated analogously in prospective, well-controlled 
clinical studies of large samples of diverse patients across multiple institutions. Phase four is the cancer 
control phase, comprising large-scale population studies to evaluate both the role of the biomarkers in 
detecting disease and the overall impact of screening in the population [127,128]. Not all biomarkers 
however will need to progress consecutively through all of the phases outlined here. 
4.2. miRNAs as Reliable Markers 
The ideal biomarkers should fit a number of criteria: To show satisfactory predictability and the 
ability to be inspected during onset, progression and/or regression of the disease, to be easy to assay and 
applicable to automatic high-throughput technology [108,129–131]. Today, most of the biomarkers detected 
in cancer patients are proteins, such as prostate specific antigen (PSA) for prostate cancer, alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) for hepatocellular carcinoma, etc. However, 
the protein assay procedure is not always easy to apply in clinical diagnosis and remains labor-intensive. 
Moreover the complexity of protein composition, post translational protein modifications, proteolysis and 
denaturation, as well as the low abundance of the proteins of interest add to the challenge of using  
proteins as successful biomarkers [132]. As a result, only a few of those protein-based biomarkers have  
been approved to be used in the diagnosis of cancer. Considering the limitations of current cancer 
conventional biomarkers, the use of miRNAs as tumor markers has aroused intense research interests, 
in particular after the discovery that profiling of miRNA expression patterns was more useful than the 
equivalent mRNA profiles [133]. In addition, contrary to mRNA which is not stable in formalin-fixed 
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paraffin-embedded tissue, miRNAs expression seems to well correlate between fresh and FFPE samples, 
possibly due to the small size and resistance to degradation of miRNAs [134,135]. Stable miRNAs have 
also been detected in body fluids including serum, plasma, urine, and other biological fluids as well as 
CSF [108,136]. Together these features make miRNAs extremely attractive for clinical research, since 
archived FFPE tissue and biological fluids is most often available, reviewed in [137]. 
It is estimated that miRNAs regulate around 30% of human protein-coding genes and their 
dysregulation has been associated with the development and progression of cancer [137]. Because 
miRNAs play many roles in diverse aspects of cancer, such as proliferation, apoptosis, invasion, 
metastasis, and angiogenesis, their expression pattern can be used to characterize tumor type, stage,  
or other clinical variables. They also play an active role in the etiology or progression of cancers by 
regulating the expression of oncogenes and tumor-suppressor genes. Thus, they could have potential for 
future cancer diagnosis and prognosis. Recently various studies have successfully identified the histotype of 
tumors of unknown origin according to miRNA expression profiles [138]. miRNA profiling has also shown 
promise in classifying human cancers [133], defining malignant status [139], and accurately identifing 
cancer tissue origin. Furthermore, evaluation of miRNA expression has been found to be of great  
prognostic [140,141] and diagnostic value [142,143]. Additionally, miRNA expression was shown to provide 
promising biomarkers for the outcome prediction of a wide array of human cancers [138,143,144],  
as well as for predicting the response to chemo-radiotherapy [145,146]. 
Utilization of automatic high-throughput technology for precise measurements is a fundamental 
analytical issue that needs to be fulfilled in molecular marker assays. In this regard the widespread and 
comprehensive use of high-throughput miRNA technologies, such as amplification-based quantitative 
real-time PCR (q-RT-PCR), hybridization-based microarrays, and sequencing-based next-generation 
sequencing (NGS) technologies, have enabled the accurate quantification of miRNA expression and the 
identification of miRNAs uniquely expressed in cancers [147]. Advanced technologies not only help to 
identify the oncogenic and tumor suppressor potentials of miRNAs, but also assist in providing a more 
comprehensive understanding of their underlying mechanisms and pathways. In summary, features of 
miRNAs such as rich information content, great discriminatory power, stability, accessibility in different 
specimen types, possibility of being evaluated from different sources, and finally, and importantly, their 
potential for highly sensitive measurement, have qualified them as reliable biomarkers. In fact, some 
tests using miRNA as biomarkers for clinical diagnosis are now available. Rosetta Genomics offers three 
different tests designed to identify specific miRNA signatures and use them to accurately diagnose 
diseases and predict their progress. Another company, Asuragen, has developed tests to diagnose 
pancreatic and colorectal cancer, as well as leukemia [12]. 
4.3. Challenges 
Application of miRNA profiling approaches for many malignancies, including CNS embryonal 
tumors, has produced hundreds of candidate biomarkers for detection and prognostication [40,64,68,69,87], 
yet none have become established in clinical practice. Fundamental issues have slowed the progress  
of clinical deployment, mainly the lack of clinically relevant animal models for miRNA research. 
Therefore, the creation of a suitable, well-defined and validated animal model is essential to elucidate 
the role of miRNAs in embryonal tumors and to transfer knowledge from bench to bedside and so to 
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address clinical questions [148]. Other factors contributing to the failure of candidate biomarkers to 
realize clinical utility include those inherently associated with conventional biomarkers such as (i) lack of 
collaborative research efforts; (ii) availability of tumor tissue samples; (iii) reliability and reproducibility 
of results; (iv) variability of biomarker assessment methods; (v) expenses involved with assessing the 
marker status; (vi) the need for developing new miRNA assessment technologies; and (vii) lack of cellular 
and clinical database resources. 
4.3.1. Lack of Collaborative Research Efforts 
Most of the miRNA alterations in embryonal brain tumors have been identified by research groups 
studying small numbers of retrospectively collected tumor samples, and using different experimental 
methods and protocols. The generated data and results are therefore difficult to compare, statistically 
underpowered, and do not successfully result in the development of fully validated biomarkers [149–153]. 
Hence there is a great need to facilitate the transition and incorporation of miRNA biomarker research 
from single research groups to a more collaborative approach. Large strategic research partnerships and 
international collaborative projects should be developed between pediatric brain tumors labs. Efforts to 
develop and validate miRNAs as biological markers for pediatric brain tumors should be shared between 
different international labs, research responsibility should be divided, and duties should be clear. 
Initiatives are also needed tounitebasic and clinical researchers and promote their collaboration. It is vital 
to link clinicians and researchers of molecular measurements in order that experimentation becomes 
clinical reality. Collaborative and integrative research, proper communication and understanding among 
pediatric brain tumors labs worldwide are key methods of uniting the skills necessary for developing 
successful biomarkers. 
4.3.2. Availability of Tumor Tissue Samples 
To date, most of the investigations into the use of miRNAs as biomarkers have been performed mainly 
in cell lines or animal models while other studies included only small cohorts of patient samples that 
were not validated in prospective clinical trials. A final decision for human use must be based on results 
derived from clinical trials with an adequate number of patient samples that represent a proof of concept 
for the field of miRNAs as biomarkers. The sensitivity and specificity of a molecular marker cannot  
be fully realized until careful testing is carried out in tumor specimens and compared with normal  
controls [123,154–158]. Therefore, access to well-preserved human tissues accompanied by high quality 
clinical data is a prime issue to be considered in order to examine the relationship between molecular 
changes and clinical variables or outcomes. The collected specimens usually include tumors, as well as 
adjacent normal tissues when possible and are associated with a spectrum of information that usually 
includes the collection time, the tissue composition and the alterations within that reflect the type and 
stage of disease (histopathology). The small number of available tumor tissue samples however has 
disappointingly limited the output of researchers in the field of rare tumors, such as embryonal brain 
tumors, and the clinical translation of many candidate miRNA markers is stalled by the lack of  
well-characterized tissue samples [154–158]. An analysis of biomarker publications showed that many 
individual studies report high association between specific biomarkers and disease outcome; however 
when the same marker is subsequently compared with larger studies, or meta-analyses, the effect size is 
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often significantly smaller than initially believed [159]. This has brought recognition to the urgent need  
to improve the availability and access to tissue resources. Tumor collections by single institutions or 
individual scientists are mostly not sufficient to address these resource problems. Therefore, improved 
tools such as biobanks, one of the key resources in the fight against cancer, are certainly needed [160–162]. 
However, unlike other research tools such as cell lines and animal models, the biobank boom spawned an 
increase of regulations and guidelines, which has created controversies, particularly about the importance 
and definition of informed consent [163–165] that is required before biobank samples can be collected 
and used in research. Unclear, conflicting, or burdensome regulatory requirements and lack of agreement 
among clinicians, investigators, and regulators as well as the nature of this consent and how it is obtained 
add another layer of complexity to the sample collection matter. Some European guidelines take the 
view that general consent is acceptable to use samples for future, as yet unspecified research projects; 
US and Canadian policy follows a more rigorous standard of consent [163]. 
4.3.3. Reliability and Reproducibility of Results 
Acquisition of highly reproducible data is necessary to produce reliable markers that could be used 
in clinical situations. However, the lack of standardization that is manifested in the variability in 
experimental conditions, methodology, measurements, protocols, and platforms, is another very 
important factor that challenges the process of miRNAs biomarker validation process. There is 
skepticism and legitimate debate within the research community on what is needed to be done to translate 
laboratory findings into tangible clinical applications [166]. The skepticism is partially derived from 
some inflated expectations, which are frequently followed by disappointment when the original results 
of certain investigations could not be reproduced. As is known from the field of microarrays, data is 
often incomplete or incompletely annotated and the analyses are hard to reproduce [167]. For example, 
four different research groups have reported miRNA profiles for pancreatic cancer, with impressive 
discrepancies between the results [12,168–170]. 
4.3.4. Variability of Biomarker Assessment Methods 
Another key factor that hampers the validation of biomarkers and contributes to the failure of 
candidate biomarkers to realize clinical utility is the multitude and variety of sample processing, RNA 
extraction and expression measurement/assessment methods. Equally important are the differences in 
specimen type, for example FFPE vs. fresh frozen samples. Studying miRNA profiles involves sample 
collection; miRNA detection; analytical platform and protocols, data processing; statistical analysis, and 
clinical interpretation [12]. A variety of these analytic techniques exists, each with specific biases that 
can greatly influence the relative weight of certain miRNA molecules in the tested sample. No wonder 
there is often a low correlation of results obtained from different platforms or even from the same 
platform using kits and reagents from different vendors. These are especially pronounced when  
a highly sensitive technique like sequencing is used. Currently there are no universally implemented 
guidelines for the collection, preparation, and extraction of samples for miRNA analysis. Standardization 
of these assays is a challenge for the near future. Data normalization, an often underestimated aspect of 
data processing, is as well crucially important and a major concern in obtaining accurate results [171]. 
Therefore, it is important to be methodologically consistent across different samples and steps must be 
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taken to carefully select miRNA-profiling platforms and data analysis methods for the acquisition  
of clinically meaningful and dependable data. Furthermore, standardization of miRNA biomarker 
evaluation is definitely needed. 
4.3.5. Expenses Involved with Assessing the Marker Status 
It has been difficult to translate molecular markers to the clinic, owing to not only the above 
mentioned factors, but also due to the vast expense that is involved in developing the necessary platforms 
and technology for testing different assays in a prospective clinical trial. Indeed economic and business 
considerations can slow cancer biomarker development. Appropriate finance to provide clinical 
opportunities for the evaluation of new technologies, reagents and assays is lacking and industrial 
companies do not play a role in most pediatric disease research. Many of the miRNA diagnostic and 
prognostic markers that have been reported in the literature are in the public domain and lack intellectual 
property protection. Companies have shied away from developing clinical tests in the absence of this 
protection. It has to be said, however that the miRNA-based biomarker development problems are not 
only concentrated in the pediatric brain tumor field. There has been a huge increase in intellectual 
endeavors concerning research devoted to the discovery and validation of other disease biomarkers 
within both the biological and clinical sciences during the last decade. For instance, in searching for the 
term “biomarker” in the literature database, more than 660,000 published articles could be found. 
However, these enormous investments and academic output have not yet translated into the expected 
integration of new biomarkers for patient care [172]. 
4.3.6. The Need for Developing New miRNA Assessment Technologies 
There is still no clear-cut consensus as to what is the best approach to analyze large-scale miRNA 
profiles. It is expected that these issues will settle with time, as techniques become more robust and 
analysis methods stabilize [173]. Refining, and/or developing, new detection and measurement 
technologies with improved analytic tools that allow more detailed examinations of the molecular and 
cellular signatures of pediatric brain tumors is an important task that is needed for the development of 
successful miRNA biomarkers and efficacious target gene therapy discovery [174]. It is estimated that 
non-coding RNAs involved in cancer may include over 1500 miRNAs. Such complexity clearly 
highlights the need for ultra-high resolution technology for robust quantitative miRNA measurements 
and data acquisition as well as to analyze already discovered potential markers in a cost-effective  
fashion [123]. Development of new measurement technologies therefore is central to successful 
biomarker development and should be strongly encouraged. 
4.3.7. Lack of Cellular and Clinical Database Resources 
Databases play a major role in cancer research at the cellular and clinical levels, with a central role 
currently played by expression array data. Global electronic database gathering and storing a wide range 
of data for genetic variations and miRNA expression profiles that are pediatric brain tumor-relevant must be 
developed and sustained [174]. Web-service technology linking molecular level databases and biobank 
data as well as software platforms for data and document management, facilitating remote communication 
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between biomarker development’s concerned parties should be encouraged. A common information 
infrastructure for data exchange, analysis and modeling and meta-analysis methodologies should be put 
into practice, thereby allowing researchers the choice between going through lots of papers published 
over the past several decades on individual experiments, or more simply using high throughput datasets. 
All in all we are just starting to uncover the huge potential of miRNAs as novel biomarkers for 
medicine. However, as mentioned above, conceptual and technical issues still need to be overcome. 
Moreover there are still many questions remaining unanswered in understanding miRNA biology and 
function, and as yet, not all the enzymes and proteins involved in miRNA production and processing are 
known [175]. We have not identified other factors contributing to miRNA-target gene recognition, other 
than seed sequence complementarities, nor the actual regulation of miRNAs at the transcriptional level. 
It is still unclear how cancer cells manipulate miRNAs and other regulators to promote their own survival 
and growth under stressed tumor microenvironments [176]. A more thorough understanding of  
miRNA biology is certainly needed before candidate biomarkers realize clinical utility. However, despite 
current limitations, miRNA-based biomarkers constitute an exciting field in biomedical research and it 
is likely to become a routine approach to generate individual patient profiles and allow targeted 
therapeutic intervention. 
5. Therapeutic Potential of miRNAs 
5.1. miRNAs as Druggable Targets 
As noted above, several miRNAs are altered in pediatric brain tumors disease states when compared 
to the normal brain. Whether this differential expression occurs as a consequence of the pathological 
state or whether the disease is a direct cause of this differential expression is currently unknown. 
Nonetheless, since miRNAs are deregulated in cancer, it is thought that normalization of their expression 
could be a potential method of intervention. In this vein, several therapeutic mechanisms have been put 
forth and are described [177–179]. Generally there are two approaches to develop miRNA-based 
therapeutics: miRNA antagonists [70,180] and miRNA mimics/replacement [181]. miRNA antagonists 
inhibits endogenous miRNAs that show a gain of function in cancer tissues. This approach is 
conceptually similar to short interfering RNAs (siRNAs). It usually involves the introduction of anti-miR  
or antago-miR that bind with high affinity to the active miRNA strand and results in its degradation.  
On the other hand, miRNA mimics/replacement are used to restore a loss of function. This approach 
aims to re-introduce miRNAs into diseased cells that are normally expressed in healthy cells. miRNA 
mimics can be delivered systemically using technologies that are also used for therapeutic siRNAs [181]. 
There are several significant advantages of miRNAs for becoming a new class of drug targets.  
Their small size and known and conserved sequence make them attractive candidates from a 
development standpoint. Moreover, many genetic or oligonucleotide-based gain- and loss-of function 
studies have shown very pronounced phenotypes in rodents and even large animal models,  
whereas miRNA manipulation under baseline conditions usually does not exert overt effects. 
Furthermore, and importantly, the direct downstream targets of a single miRNA are commonly related 
genes that function in a comparable cellular process or signaling cascade. This implies that targeting of 
Int. J. Mol. Sci. 2014, 15 21573 
 
 
a single miRNA will probably result in a dramatic effect due to the combinatorial effect of gene 
expression changes in all these related downstream targets, reviewed in [182]. 
5.2. miRNAs as Predictors and Modifiers of Chemo- and Radio-Therapy 
Perhaps the most promising application of miRNAs might lie in the estimation of outcome and 
response of well-established anti-tumor therapies, such as chemotherapy and radiation. For example,  
it has been recently shown that alterations in miRNA expression profiles could provide predictive 
information about sensitivity or resistance of certain tumor types to different treatments; alternatively, 
or in addition, changes in expression during a therapy might offer a tool for treatment response 
monitoring. Finally, modification of miRNA expression by up- or down-regulation may possibly 
enhance sensitivity to the applied chemo- or radio-therapy, reviewed in [183]. Extensive profiling studies 
on cancer cell line, animal xenographs, and tumors, have associated miRNA expression in cancer cells 
with chemo- and radio sensitivity, both with regards to predicting or modulating sensitivity. Several 
miRNAs have been found to predict sensitivity to anticancer treatment, while others were shown to 
influence sensitivity to chemo- or radio-therapy in vitro and/or in vivo. There are many potential roles 
for miRNAs in altering chemotherapeutic response that have been reported in the literature. For example, 
miRNA replacement or silencing may be used to augment chemotherapeutic effects [184,185] or 
alternatively to base the selection of traditional chemotherapies on their ability to deregulate specific 
panels of miRNAs [186]. Perhaps the most clinically applicable approach is to use miRNA signatures to 
guide chemotherapeutic decisions. In vitro studies have identified miRNAs whose expression patterns 
correlate with drug response [187,188]. However, global profiling studies have been used as classifiers of 
responders vs. non responders in various cancers [186,189]. miRNAs may modulate the DNA damage 
response, thus sensitizing tumor cells to both chemotherapy and radiotherapy [190,191]. The role of 
miRNAs as sensitizers to radiotherapy is of particular importance given the fact that many pediatric 
brain tumors in infants and young children require combinations of chemotherapy and high doses of 
spinal radiotherapy as optimal modes of treatment. In this case infants could be treated with a 
substantially less toxic treatment strategy. 
5.3. Challenges of miRNA-Based Therapies 
Although there are many reasons to be excited about miRNAs as a new class of drug targets,  
some aspects of miRNA and anti-miRNA biology are still relatively unknown and the majority of the 
promising miRNA targeting approaches are still at their preclinical stage. The optimization of the 
stability of miRNAs, the improvement in delivery systems, and targeted drug delivery as well as the 
understanding and control of off-target effects of miRNA therapeutics, are the main challenges for their 
future development. Similar to small interfering RNA therapies, difficulties of specific delivery, and the 
insufficient uptake for effective target inhibition challenge the development of miRNA-based therapies. 
Despite the fact that chemical adaptations in oligonucleotides, such as cholesterol conjugation and 
phosphorothioate backbone modifications, were able to overcome these obstacles, impaired biological 
activity and increased toxicity usually accompanied the resulted improved delivery to tissues [192]. 
Moreover it is expected that tumor types and context will add to the complexity and heterogeneity of 
response to any miRNA therapy strategies. Blood-brain barrier (BBB) forms another important hurdle 
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for effective miRNA treatment of malignant brain cancer. Hence, effective brain delivery for miRNAs 
may require the design of particular therapeutic approaches that overcome this physiological obstruction, 
such as the use of nanoparticles, immunoliposomes, peptide vectors or carrier-mediated transport 
through the BBB, reviewed in [193]. New therapies targeting miRNAs or their target genes may best be 
applied in the future together with molecular profiling of cancers for clinical stratification and selection 
of combination therapies. 
6. Concluding Remarks 
miRNAs are revolutionizing the field of cancer research. The emerging role of their dysregulation in 
human cancer has raised exciting opportunities as well as challenges for their clinical application in the 
capacity of cancer detection and prediction. 
In the therapeutic arena, the realization that the inappropriate production of individual miRNAs 
contributes to several aspects of carcinogenesis suggests that inhibition of overexpressed oncogenic 
miRNAs or substitution of tumor suppressive miRNAs could become a novel treatment strategy or a 
promising candidate for treatment response prediction or for modulation of conventional anticancer 
treatment sensitivity. With the advent of high-throughput technologies for the global measurement of 
miRNAs, research has shown miRNAs to have potential as biomarkers for the diagnosis and prognosis 
of pediatric brain tumors. However most miRNA studies have been limited to the preclinical discovery 
stage. The challenge remains to optimize and to validate miRNA biomarkers through carefully designed 
translational/clinical studies. Such studies require careful practical consideration of the best methods for 
sample collection, miRNA isolation, quantification, and data analysis and importantly to translate this 
wealth of discovery into clinical management of pediatric brain tumors patients. It is likely that 
significant progress will be achieved in the usage of miRNAs in cancer diagnosis and outcome prediction 
in the near future, and undoubtedly, the coming years will bring exciting new therapeutic strategies based 
on the targeting of miRNA in the treatment of human cancer. It is hoped that some of these will be 
efficient and beneficial for pediatric brain cancer patients. 
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